TYROGENEX
Tyrogenex, Inc., a biotechnology company, engages in research and development of multi-kinase angiogenesis inhibitor for the treatment of solid tumors. The company has developed a novel, patented cancer therapeutic, X-82, a dual VEGFR/PDGFR inhibitor. The company was formerly known as Xcovery, Inc. The company was incorporated in 2006 and is based in West Palm Beach, Florida. The company operates as a subsidiary of Xcovery LLC.
TYROGENEX
Industry:
Biotechnology Medical Device Therapeutics
Founded:
2006-01-01
Address:
West Palm Beach, Florida, United States
Country:
United States
Website Url:
http://www.tyrogenex.com
Total Employee:
1+
Status:
Active
Contact:
+1 (855) 978-7025
Total Funding:
21.4 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Apple Mobile Web Clips Icon Google Font API WordPress Font Awesome Contact Form 7 COVID-19 WordPress 6.0
Similar Organizations
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Scholar Rock
Scholar Rock is a biopharmaceutical company that develops and discovers new medicines and treatments for the serious diseases.
Siva Therapeutics
Siva Therapeutics is a biotechnology company developing nanotechnology approaches for treating cancer.
Current Employees Featured
Founder
Investors List
Brace Pharma
Brace Pharma investment in Series D - Tyrogenex
More informations about "Tyrogenex"
Tyrogenex, Inc. Company Profile | Rockville, MD | Competitors ...
Find company research, competitor information, contact details & financial data for Tyrogenex, Inc. of Rockville, MD. Get the latest business insights from Dun & Bradstreet.See details»
Tyrogenex - Contacts, Employees, Board Members, Advisors
Tyrogenex is a biotechnology company researching and developing treatments for solid tumors.See details»
Tyrogenex - VentureRadar
"Tyrogenex is affiliated with Xcovery Holdings. It was founded by Sheridan (Sherry) Snyder through Biocatalyst International in partnership with Dr. Chris Liang. Through this partnership, …See details»
Tyrogenex, Inc. Company Profile | North Palm Beach, FL
Find company research, competitor information, contact details & financial data for Tyrogenex, Inc. of North Palm Beach, FL. Get the latest business insights from Dun & Bradstreet.See details»
BIO2015: Tyrogenex, Inc. And Xcovery Open New Office In Needham
Jun 18, 2015 Needham, MA and Philadelphia, June 18, 2015 – Tyrogenex, a leader in the development of novel kinase inhibitors to target angiogenesis, and Xcovery, a developer of …See details»
Tyrogenex - Funding, Financials, Valuation & Investors
Tyrogenex is a biotechnology company researching and developing treatments for solid tumors.See details»
Organization | Tyrogenex - Purdue University
Tyrogenex Report issue For profit Phase 1 Phase 2 Founded: West Palm Beach FL United States (2006) Status: Defunct (2020) Organization Overview First Clinical TrialSee details»
Tyrogenex and Xcovery Open New Office in Needham
Jun 18, 2015 Needham, MA and Philadelphia – Tyrogenex, a leader in the development of novel kinase inhibitors to target angiogenesis, and Xcovery, a developer of next-generation targeted therapeutics for cancer, today …See details»
Tyrogenex | VentureRadar
Tyrogenex is affiliated with Xcovery Holdings. It was founded by Sheridan (Sherry) Snyder through Biocatalyst International in partnership with Dr. Chris Liang. Through this partnership, …See details»
Tyrogenex, Inc., Xcovery Appoint Michael Webb As President And …
Apr 2, 2015 The boards of both companies appointed Webb, who has been CEO of four biotechnology companies as well as chairman of the MassBio industry organization, as …See details»
Tyrogenex - Crunchbase
Tyrogenex is a biotechnology company researching and developing treatments for solid tumors.See details»
Vorolanib - Drug Targets, Indications, Patents - Synapse - Patsnap
Vorolanib: a PDGFR antagonists, VEGFR antagonists Drug, Initially developed by Tyrogenex, Inc., Now, its global highest R&D status is Approved, Mechanism: PDGFR antagonists …See details»
Tyrogenex begins Phase II trial of oral treatment with X-82 to treat ...
Apr 29, 2015 US-based Tyrogenex has started a Phase II trial (Apex) of its orally administered drug candidate, X-82, for the treatment of wet age-related macular degeneration (AMD) in …See details»
Tyrogenex Completes Patient Enrollment in its Phase 2 Trial of …
Mar 9, 2017 Tyrogenex announced the completion of patient enrollment in its phase 2 trial of X-82 (vorolanib) for the oral treatment of wet age-related macular deSee details»
Vorolanib - Betta Pharmaceuticals/Tyrogenex - AdisInsight
Aug 19, 2024 Contacting your organization’s admin about adding this content to your AdisInsight subscription Buying a PDF version of any individual profile Request a free trial If your …See details»
Tyrogenex Announces Publication of Phase 1 Data for X-82 for the …
Jun 8, 2017 Tyrogenex today announced that the Journal of the American Medical Association (JAMA Ophthalmology) has published the results from its Phase 1 dose-esSee details»
Tyrogenex - Updates, News, Events, Signals & Triggers
Mar 31, 2015 Tyrogenex is a biotechnology company researching and developing treatments for solid tumors.See details»
Tyrogenex - Tech Stack, Apps, Patents & Trademarks
Tyrogenex is a biotechnology company researching and developing treatments for solid tumors.See details»
Oral Tyrosine Kinase Inhibitors for Neovascular Age-Related …
To the Editor We recently reported a phase I dose-escalation study of the oral tyrosine kinase inhibitor vorolanib (previously known as X-82 [Tyrogenex]), which was used as a treatment for …See details»